Literature DB >> 8341987

Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin.

E Bayerdörffer1, G A Mannes, A Sommer, W Höchter, J Weingart, R Hatz, N Lehn, G Ruckdeschel, P Dirschedl, M Stolte.   

Abstract

Early studies have suggested that omeprazole may facilitate the eradication of Helicobacter pylori. Sixty patients with duodenal ulcer and H. pylori colonization were randomly assigned to receive either omeprazole monotherapy (n = 30) or combination therapy with omeprazole and amoxycillin (n = 30) for a total duration of 6 weeks. Four patients receiving monotherapy and three receiving combination therapy had to be withdrawn from the study. All (100%) duodenal ulcers healed in patients receiving combination therapy, and 25 out of 26 (96%) healed in the group receiving monotherapy. H. pylori was eradicated in 22 out of 27 (82%) patients receiving combination therapy; only two ulcer relapses (9%) occurred within 18 months in these 22 patients. Of the five patients who remained H. pylori-positive after combination therapy, two relapsed during the 18-month follow-up. In the monotherapy group, all patients remained H. pylori-positive after treatment, and duodenal ulcer relapsed in 16 out of 25 (64%) patients within the median follow-up of 18 months. Adverse events were not reported in the group treated with combination therapy; one patient receiving monotherapy reported severe headache. These results lend further support to existing data that H. pylori eradication prevents duodenal ulcer relapse and show that combination therapy with omeprazole and amoxycillin is effective and well tolerated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8341987     DOI: 10.3109/00365529309098337

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  13 in total

1.  Use of PCR and culture to detect Helicobacter pylori in naturally infected cats following triple antimicrobial therapy.

Authors:  S E Perkins; L L Yan; Z Shen; A Hayward; J C Murphy; J G Fox
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 2.  We need to integrate new data concerning Helicobacter pylor into experimental ulcer research.

Authors:  D Y Graham
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

Review 3.  Gastroenterology--I: Gastroduodenal disease and Helicobacter pylori.

Authors:  M C Bateson
Journal:  Postgrad Med J       Date:  1994-08       Impact factor: 2.401

4.  Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments.

Authors:  F Catalano; G Branciforte; A Brogna; C Bentivegna; S Luca; R Terranova; A Michalos; B K Dawson; H B Chodash
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

Review 5.  A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection.

Authors:  A Hackelsberger; P Malfertheiner
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

6.  Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial.

Authors:  R Behrens; T Lang; K M Keller; L Bindl; M Becker; B Rodeck; P Küster; G F Wündisch; M Stolte
Journal:  Arch Dis Child       Date:  1999-07       Impact factor: 3.791

7.  Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high- and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study.

Authors:  Kazuhide Higuchi; Takama Maekawa; Koichiro Nakagawa; Shinji Chouno; Takanobu Hayakumo; Naomi Tomono; Akio Orino; Hirohisa Tanimura; Kan Asahina; Naotaka Matsuura; Motohiko Endo; Masanori Hirano; Choitsu Sakamoto; Tsutomu Inomoto; Tetsuo Arakawa
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 8.  Role of Helicobacter pylori in gastrointestinal disease: implications for primary care of a revolution in management of dyspepsia.

Authors:  B C Delaney
Journal:  Br J Gen Pract       Date:  1995-09       Impact factor: 5.386

9.  Does seropositivity for Helicobacter pylori antibodies increase outpatient costs for gastric and duodenal ulcer or inflammation?

Authors:  Akira Babazono; Motonobu Miyazaki; Hiroshi Une; Eiji Yamamoto; Toshihide Tsuda; Yoshio Mino; Alan L Hillman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 10.  Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people.

Authors:  Alexander C Ford; Kurinchi Selvan Gurusamy; Brendan Delaney; David Forman; Paul Moayyedi
Journal:  Cochrane Database Syst Rev       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.